Npt2b Deletion Attenuates Hyperphosphatemia Associated with CKD

Susan C. Schiavi, Wen Tang, Christina Bracken, Stephen P. O’Brien, Wening Song, Joseph Boulanger, Susan Ryan, Lucy Phillips, Shiguang Liu, Cynthia Arbeeny, Steven Ledbetter, and Yves Sabbagh

The Sanofi-Genzyme R&D Center, Genzyme, a Sanofi Company, Framingham, Massachusetts

ABSTRACT

The incidence of cardiovascular events and mortality strongly correlates with serum phosphate in individuals with CKD. The Npt2b transporter contributes to maintaining phosphate homeostasis in the setting of normal renal function, but its role in CKD-associated hyperphosphatemia is not well understood. Here, we used adenine to induce uremia in both Npt2b-deficient and wild-type mice. Compared with wild-type uremic mice, Npt2b-deficient uremic mice had significantly lower levels of serum phosphate and attenuation of FGF23. Treating Npt2b-deficient mice with the phosphate binder sevelamer carbonate further reduced serum phosphate levels. Uremic mice exhibited high turnover renal osteodystrophy; treatment with sevelamer significantly decreased the number of osteoclasts and the rate of mineral apposition in Npt2b-deficient mice, but sevelamer did not affect bone formation and rate of mineral apposition in wild-type mice. Taken together, these data suggest that targeting Npt2b in addition to using dietary phosphorus binders may be a therapeutic approach to modulate serum phosphate in CKD.


Elevated serum phosphorus even within the normal range is emerging as an important health risk in both normal and CKD populations because it is associated with increased incidence of vascular calcification and mortality. Elevated serum phosphorus even within the normal range is emerging as an important health risk in both normal and CKD populations because it is associated with increased incidence of vascular calcification and mortality.1,2 Although current CKD therapies such as phosphate binders effectively decrease serum phosphorus by reducing the pool of absorbable phosphate, management of serum levels remains difficult. A limited understanding of the complexity associated with phosphate regulation has slowed development of optimal therapeutic strategies.

It is well accepted that in normal physiology, the kidney disposes of excess phosphate absorbed by the intestine or released from bone through well characterized, regulated mechanisms. The intestine has been largely viewed as a passive component because the available evidence suggested that the major route of phosphate entry is via paracellular transport driven by diffusion.3–5 We have recently challenged this dogma by conditionally deleting the intestinal sodium-dependent phosphate co-transporter, Npt2b, in adult mice.6 By mimicking postprandial conditions to maximize contributions of both passive and active transport, Npt2b-dependent phosphate transport was shown to contribute to as much as 50% of the total phosphate uptake.6 Using the everted sac method, we also confirmed that >90% of active transport occurs through Npt2b. Most importantly, Npt2b−/− mice maintained serum phosphorus within the normal range by decreasing the phosphaturic hormone, fibroblast growth factor 23 (FGF23), upregulating renal Npt2a protein expression and subsequently decreasing urinary phosphorus excretion.6 These studies demonstrated that Npt2b is an important route...
for phosphate absorption and participates in the regulation of renal phosphate handling.

Several lines of evidence suggest that inhibition of Npt2b-dependent transport may attenuate the phosphate burden in the absence of a functional kidney. Phosphate lowering effects have been shown in preclinical models and in humans treated with either nicotinamide or its precursor, niacin.7–10 Nicotinamide has been shown to inhibit sodium-dependent phosphate transport activity in rat small intestine, reduce Npt2b mRNA expression, and attenuate hyperphosphatemia in an adenine-induced renal failure model.11,12 Reduction in serum phosphate with corresponding modulation of Npt2a and 2b mRNA expression has also been observed in rats treated with liver X receptor agonists.13 These data cumulatively support the possibility that inhibition of this transporter may be a viable therapeutic alternative. Nonetheless, these agents are also known to have pleiotropic actions, which may also contribute to changes in mineral homeostasis.12,14 A recent study in uremic Npt2b+/− mice provides initial evidence that Npt2b reduction specifically decreases hyperphosphatemia.15 However, because this study was performed using developmental heterozygous mice with ARF, it is unknown whether the effects of Npt2b deletion can be sustained over the course of CKD progression due to upregulation of Npt2a. In addition, bone disease, a known contributor of systemic phosphate burden, was likely not present in this acute model. There are also several inconsistent reports regarding changes in Npt2b expression in uremic models that have generated skepticism for successfully targeting Npt2b in late stage CKD.16,17

In this study, we have examined the long-term effects of reducing Npt2b expression on mineral dysregulation associated with CKD. Hyperphosphatemia was significantly reduced over 5 weeks in uremic Npt2b−/− mice. Furthermore, phosphate binding and Npt2b deletion effects were synergistic as evidenced by serum, urinary, and fecal phosphorus parameters. Significant improvements on bone histomorphometric parameters were also observed in sevelamer-treated uremic Npt2b−/− mice further demonstrating that improved phosphate control led to enhanced benefits on CKD-mineral bone disorder parameters. Taken together, these studies extend previous results by validating the specific role of Npt2b in hyperphosphatemia in a chronic CKD model with high turnover renal osteodystrophy.

RESULTS

Npt2b Expression in Uremic Mice
To assess the contribution of Npt2b to hyperphosphatemia, kidney injury was introduced by adenine treatment of wild-type (WT) or conditional Npt2b−/− mice.6 These studies utilized our previously characterized model in which Npt2b deletion in adult mice is driven by a tamoxifen-inducible CRE system.6 Parallel studies were performed in animals fed 1% sevelamer carbonate to compare relative effects of deleting Npt2b with phosphate sequestration. Immunostaining of intestinal sections clearly detected Npt2b protein expression on the villi surfaces of ileum in all WT but not Npt2b−/− mice (Figure 1A). These findings were confirmed by quantitative immunoblot analysis (Figure 1, C and D). A trend toward reduced Npt2b protein expression was observed in uremic WT mice relative to normal mice (Figure 1D). In contrast, sevelamer treatment led to a significant increase in Npt2b protein expression (Figure 1D).

Phenotypic Characterization of Normal and Uremic Mice
Mice with normal kidney function (WT or Npt2b−/−) had similar age-related changes in body weight (Figure 2B), whereas adenine treatment was associated with an approximately 25%–40% reduction in food intake, decreased body weights, and reduced renal function (Figure 2, B and C). Maximal decline in renal function was observed after 2 weeks of adenine treatment with some recovery noted upon adenine withdrawal (Figure 2C). Histologic analysis demonstrated that all uremic groups had moderate to severe renal tubulointerstitial pathology characterized by tubular dilation and/or atrophy, epithelial cell degeneration, necrosis and regeneration, interstitial inflammation, and mild peri-tubular fibrosis (data not shown). There were no detectable differences in renal function across the uremic groups. Histologic analysis of ilial sections from uremic WT or Npt2b−/− mice did not provide evidence of adenine associated toxicity (Figure 1B).

Npt2b Deletion Attenuates Chronic Hyperphosphatemia
WT and Npt2b−/− mice had similar serum phosphate levels as previously described (Figure 3A).6 At 2 weeks, WT mice were significantly hyperphosphatemic, whereas Npt2b−/− mice had a slightly lower serum phosphate (Supplemental Figure 1). In contrast, sevelamer treatment led to a significant decrease in Npt2b−/− mice relative to WT treated mice (Supplemental Figure 1). However, after 5 weeks of uremia, WT mice were significantly hyperphosphatemic (6.88 ± 0.31 versus 10.04 ± 0.51 mg/dl), whereas the Npt2b−/− mice had an attenuated increase in serum phosphate levels (10.04 ± 0.51 versus 8.21 ± 0.56 mg/dl). At the dose tested (1%), binder treatment did not alter serum phosphate levels in uremic WT mice (10.04 ± 0.51, untreated versus 9.67 ± 0.69, binder-treated mg/dl) but further decreased serum phosphate levels in uremic Npt2b−/− mice (6.88 ± 0.31; binder-treated versus 8.21 ± 0.56 mg/dl; untreated) (Figure 3A). Serum calcium levels were similar between WT and Npt2b−/− mice although a statistically significant increase was noted in all sevelamer-treated animals (Figure 3B).

Correlation analysis of serum BUN with serum phosphate of WT and Npt2b−/− mice demonstrated that Npt2b deletion shifts the phosphate slope to the right (Figure 4A). Analysis of the slope of best-fit linear regression for the different treatment groups reveals that uremic WT mice treated with

Figure 1)
sevelamer carbonate and nontreated uremic Npt2b\(^{-/-}\) mice have a decreased slope. In addition, uremic Npt2b\(^{-/-}\) mice treated with binder have a significantly lower slope relative to untreated mice (Figure 4B).

The attenuated serum phosphate response in the adenine-treated Npt2b\(^{-/-}\) mice was also observed in a second mouse model of CKD, the 5/6 nephrectomy (Nphx) model (Supplemental Figure 2B). The 5/6 Nphx WT mice had a significant increase in serum phosphate correlating with significant changes in BUN, whereas there was no change in serum phosphate in 5/6 Nphx Npt2b\(^{-/-}\) mice despite significant changes in renal function (Supplemental Figure 2).

The higher urinary and fecal phosphate excretion due to the higher dietary phosphate content in uremic groups obscured any potential difference between binder-treated and untreated uremic WT mice (Figure 3, C and D). In contrast, binder treatment in uremic Npt2b\(^{-/-}\) mice was associated with a significant increase in fecal phosphate excretion (29.39±5.43 versus 45.91±5.91 mg/d) with a corresponding decrease in urinary phosphate excretion (9.12±0.48 versus 6.15±0.60 mg/d) (Figure 3, C and D). These results suggest that binder treatment in combination with Npt2b deletion was associated with more robust phosphate control that translated to statistically significant changes in serum, urine, and fecal phosphate levels.

Parathyroid hormone (PTH) was significantly elevated in all uremic groups relative to nonuremic mice (Figure 5A). A non-statistical trend toward decreased PTH levels was observed only in binder-treated uremic Npt2b\(^{-/-}\) mice (Figure 5A). Serum FGF23 levels were significantly elevated in uremic WT and Npt2b\(^{-/-}\) mice relative to nonuremic mice although Npt2b\(^{-/-}\) mice had a 30% lower level of FGF23 (Figure 5B). Sevelamer carbonate treatment in uremic WT mice led to a 22% decrease in FGF23 levels, although this was not statistically different from untreated WT mice (Figure 5B). In contrast, a 50% significant reduction in FGF23 levels was observed in binder-treated compared with untreated uremic Npt2b\(^{-/-}\) mice (Figure 5B).

Figure 1. Npt2b expression in mouse ileum. (A) Immunohistochemistry on a cross-sectional area of ileum showing Npt2b protein (green) in uremic WT mice that is absent in Npt2b\(^{-/-}\) mice. Hoechst staining for nuclei (blue) and actin staining with phalloidin (red). Expression of Npt2b protein was detected in both untreated and sevelamer (Sev) carbonate–treated WT mice. (B) Hematoxylin and eosin staining of ileum sections from WT and Npt2b\(^{-/-}\) knockout mice showing normal villi structure in all the groups. (C) Representative immunoblot for Npt2b protein showing Npt2b expression in WT ileum lysates, which is absent in Npt2b\(^{-/-}\) mice. (D) Quantitation of Npt2b protein expression demonstrates significant increase in expression with binder treatment. Data expressed as mean ± SEM. \(^{#}P<0.05\) versus adenine. n=8–10/group. Scale bar, 50 \(\mu\)m in main image and 10 \(\mu\)m in inset in A; 40 \(\mu\)m in B.
Phosphate Lowering Improved Bone Health

Adenine-treated WT and Npt2b−/− mice exhibited high turnover bone disease with significant elevations in bone formation and mineral apposition rates (Figure 6, A and B). A significant reduction in the mineral apposition rate led to a consistent trend toward reduced bone formation in binder-treated relative to untreated uremic Npt2b−/− mice (Figure 6, A and B). In contrast, binder treatment did not affect bone formation and mineral apposition rate in uremic WT mice (Figure 6, A and B). Elevations in osteoid surface area were also noted in all adenine-treated groups but this parameter was not altered by Npt2b deletion and/or sevelamer treatment (Figure 6C). Although significant differences in osteoclast number were not observed in the adenine-treated mice relative to their chow controls, there was a statistically significant decrease in osteoclast numbers in uremic Npt2b−/− compared with WT mice (Figure 6D). Sevelamer treatment led to a significant decrease in osteoclast number in uremic WT mice with a trend toward further decrease in Npt2b−/− mice (P=0.06) (Figure 6D).

DISCUSSION

Recently, we and others have demonstrated an important role of Npt2b in maintaining normal phosphate homeostasis.6,15 Multiple studies provide indirect evidence that Npt2b may also participate in CKD-associated hyperphosphatemia.6,11,13,16–18 To directly assess the therapeutic potential of targeting Npt2b, we evaluated the long-term effect of Npt2b deletion in a chronic CKD model. Using a modified adenine model in which progression of renal failure was limited by adenine withdrawal while allowing development of hyperphosphatemia and high turnover bone disease, we confirmed sustained decrease in serum phosphate levels in the Npt2b−/− mice.

Our data extend recent findings using an acute uremic model demonstrating that a 50% reduction in Npt2b expression could prevent rapid development of hyperphosphatemia.15 Unlike the study reported by Ohi et al., normalization of serum phosphorus in our model was observed only with concurrent binder treatment.15 In chronic disease, renal osteodystrophy is a known contributor to serum phosphate with the link between poor bone health and cardiovascular events well documented.19–21 Therefore, in our 5-week model, high bone turnover may contribute to the phosphate burden requiring more robust phosphate management. The differences in the magnitude of phosphate control may also be related to the higher bioavailable dietary phosphate in our study, leading to a greater contribution of passive transport and increased phosphate load. This point is exemplified by our data showing that although serum phosphate was reduced in uremic Npt2b−/−, changes in urinary and fecal excretion were not observed. The high dietary phosphate levels could have also prevented the compensatory increases in Npt2a protein expression and urinary phosphate excretion that we previously reported (Figure 3D).6

Despite these experimental caveats, correlation analysis of serum BUN with serum phosphate of WT and Npt2b−/− mice demonstrated that Npt2b deletion shifts the phosphate slope to the right (Figure 4A). This analysis highlights the effects of
Figure 3. Phosphate balance restored in Npt2b−/− mice. Serum, urine, and fecal phosphate and serum calcium were measured at end of life. (A) Serum phosphate (Pi) was significantly elevated in uremic WT and this effect was attenuated in uremic Npt2b−/− mice. Sevelamer carbonate (Sev) treatment normalized serum phosphate in uremic Npt2b−/− mice, whereas no statistically significant differences were observed in WT mice. (B) Serum calcium (Ca) was not different between WT and Npt2b−/− mice, although a slight elevation in serum calcium was observed with sevelamer carbonate treatment. (C) Fecal phosphate excretion is elevated in normal Npt2b−/− mice. Uremic mice on a high-phosphate diet led to a significant increase in phosphate output. Sevelamer carbonate treatment further increased phosphate excretion in uremic Npt2b−/− mice. (D) Urine phosphate is reduced in normal Npt2b−/− mice relative to WT mice. Uremic mice on a high-phosphate diet had a significant increase in urinary phosphate excretion. Sevelamer carbonate treatment significantly decreased urinary output in uremic Npt2b−/− mice relative to untreated Npt2b−/− mice and treated WT mice. Data expressed as mean ± SEM. *P < 0.05 versus chow; #P < 0.05 versus adenine; †P < 0.05 versus WT. n=8–15/group.

decreased phosphate absorption on serum levels despite the similar degree of renal dysfunction between WT and Npt2b−/− mice (Figure 4A). Analysis of the slope of best-fit linear regression for the different treatment groups demonstrated the additive effect of Npt2b deletion with sevelamer carbonate in controlling serum phosphate (Figure 4B).

The use of the adenine-induced uremia model has been challenged by previous rat studies demonstrating histopathological changes in the intestine. In our modified adenine mouse model, intestinal tissue appeared normal by histologic analysis (Figure 1B). Furthermore, we have validated our finding that Npt2b attenuates hyperphosphatemia in renal ablated mice, a second uremic model (Supplemental Figure 2).

An important question is whether sufficient Npt2b protein exists in the presence of renal failure to warrant targeting it therapeutically. Our studies utilizing immunofluorescence demonstrate that significant Npt2b expression was present in the intestinal brush border in all uremic WT groups despite animal to animal expression variability (Figure 1, A and C). These results are somewhat consistent with studies in 5/6 nephrectomized rats in which Npt2b expression and phosphate uptake were unaltered in the uremic state.

Recent data in a progressive genetic CKD rat model showed that animals treated with 3% sevelamer carbonate or calcium carbonate had a decrease in intestinal phosphate flux. A potentially important observation in our study was that considerable interanimal variability was observed within each animal group as detected by immunoblot analysis (Figure 1C) or immunofluorescence. However, quantitation of protein expression by immunoblot demonstrated that 1% sevelamer treatment in uremic WT mice led to a significant increase in Npt2b protein expression (Figure 1D). These results might also explain why binder treatment was less efficient in phosphate control in uremic WT mice compared with uremic Npt2b−/− mice. This variability in expression may be partially explained by experimental design, in which the timing of last feeding relative to tissue collection between mice may have been different due to the lack of fasting before sacrifice. This is in line with recent studies demonstrating post-transcriptional changes in Npt2b after acute alterations in dietary phosphate intake.

It is well known that the key hormones regulating calcium and phosphate homeostasis become dysregulated in CKD. As expected, serum PTH levels were equivalently elevated in uremic WT and Npt2b−/− mice (Figure 5A). Sevelamer carbonate treatment did not alter serum PTH in WT mice and was associated with modestly decreased levels in uremic Npt2b−/− mice. As previously reported, FGF23 levels were attenuated in Npt2b−/− mice compared with WT mice (Figure 5B). Differential FGF23 levels between WT and Npt2b−/− uremic mice remained although statistical significance was not achieved. Binder treatment was associated with a trend toward reduced FGF23 in WT mice, whereas a significant decrease was observed in Npt2b−/− mice. The pattern of changes in FGF23 levels in the Npt2b−/− mice mirrored relative changes in phosphate absorption as they corresponded to parallel changes in fecal, serum, and urinary phosphate parameters. Thus, in our study, the greatest control of phosphate was associated with the most significant FGF23 changes. These observations suggest that reduction of hyperphosphatemia is a more robust modulator of FGF23 than PTH. It has been recently demonstrated that elevated FGF23 directly contributes to the pathogenesis of left ventricular hypertrophy.
Bone disease is a characteristic feature of CKD-mineral bone disorder.\textsuperscript{28–30} Evidence derived from classic clinical radiolabel studies suggests that the inability of bone to serve as a buffer for excess calcium and phosphate contributes to serum phosphate elevations and may lead to deposition of excess minerals in tissues.\textsuperscript{31,32} We therefore determined the effect of Npt2b deletion on bone disease in the adenine mouse model. Classic features of high turnover, including increased bone formation rates, elevated mineral apposition rates, and increased osteoid surface, were observed in uremic mice as an apparent consequence of elevated PTH (Figure 6). Importantly, sevelamer treatment was associated with a reduction in osteoclast activity and number, suggesting that modulation of systemic phosphate is linked to osteoclast function. These effects were more significant in binder-treated uremic Npt2b\textsuperscript{−/−} mice, the condition providing greatest phosphate control (Figure 6D). Our results are consistent with published findings demonstrating that in addition to its contribution to toward redistribution of systemic phosphate levels, bone itself is also responsive to phosphate levels. Several clinical studies examining binder-treated ESRD patients have shown benefits of phosphate management on bone.\textsuperscript{33,34} In the ovariectomized rat model of high turnover with normal kidney function, sevelamer treatment was associated with reduced osteoclast number and activity leading to improved bone quality.\textsuperscript{35} In other studies, when mice were placed on a low-phosphate diet, decreased osteoclast numbers were observed, whereas a high-phosphate diet was associated with enhanced bone resorption.\textsuperscript{36,37} Zhang \textit{et al.} demonstrated that in Dmp1 hypophosphatemic knockout mice, a reduction in the number of osteoclasts was observed.\textsuperscript{38} Importantly, normalization of serum phosphate by FGF23 antibody administration resulted in increased osteoclast numbers.\textsuperscript{38} These changes appeared to be independent of alterations in PTH or 1,25 vitamin D\textsubscript{3} but were associated with corresponding changes in the ratio of receptor activator of NF\textsubscript{κ}B ligand to osteoprotegerin. Recently, we provided evidence in a progressive genetic model of CKD that repression of the \textit{b}-catenin signaling in osteocytes was associated with an increase in the ratio of receptor activator of NF\textsubscript{κ}B ligand to osteoprotegerin.\textsuperscript{39} Because these changes were independent of observable changes in serum phosphate or PTH, it remains to be determined whether phosphate contributes directly or indirectly to osteocyte regulation of osteoclast activity in the context of CKD.

Several lines of evidence suggest that the benefits of phosphate lowering on cardiovascular health include reduction
of vascular stiffness and calcification.\textsuperscript{40, 41} We did not observe vascular calcification in our adenine-treated mice, because the C57BL/6 mouse strain used in this study is known to be resistant to the development of overt vascular calcification.\textsuperscript{42}

Our data also raise the possibility that reducing bone turnover may in turn contribute to the decreased serum phosphate in uremic Npt2b\textsuperscript{−/−} mice without altering phosphate excretion. The attenuation of high turnover may lead to redistribution or maintenance of phosphate and calcium in the bone, thereby decreasing the systemic phosphate burden. Our results suggest that along with inhibition of phosphate absorption in the gut, restoration of bone buffering capacity may be important to achieving phosphate control in the setting of CKD. Taken together, our studies demonstrate that modulating phosphate through the intestinal sodium-dependent phosphate cotransporter, Npt2b attenuated the hyperphosphatemia observed in control animals and that sevelamer carbonate treatment had an additional benefit in maintaining serum phosphate in the normal range. These effects were associated with reduced serum FGF23 and improvement in bone health. Finally, our studies support Npt2b as a molecular target for the development of novel therapeutic strategies for hyperphosphatemia. Npt2b inhibition in addition to dietary phosphorus binders may represent a new paradigm for improved phosphate management in CKD.

**CONCISE METHODS**

**Mice**

All studies were approved by the institutional animal care committee. Mice were maintained in a virus- and parasite-free barrier facility and exposed to a 12-hour light/dark cycle. The generation of the conditional knockout mice has been previously described.\textsuperscript{6} Experiments were initiated 1 week after induction of Npt2b knockdown with tamoxifen as previously described.\textsuperscript{6} Unless otherwise specified, animals were maintained on standard rodent chow diet (PicoLab Rodent Diet 20, #5053; LabDiet, St. Louis, MO) containing 0.63% phosphate, 0.81% calcium with 2.2 IU/g vitamin D₃. To induce uraemia, 0.2% adenine was added to a casein-based synthetic diet containing 0.9% phosphate and 0.6% calcium (##110457; Dyets Inc., Bethlehem, PA) for 2 weeks (Figure 2A). Then adenine was withdrawn but the mice were kept on the casein diet for another 3 weeks. Binder-treated groups received 1% sevelamer carbonate (Genzyme, Cambridge, MA) mixed in diet (Figure 2A). Animal numbers per group used are indicated in the figure legends.

**Surgical Renal Ablation**

CKD was induced in WT and Npt2b\textsuperscript{−/−} mice by the procedure previously described by Gagnon and Duguid.\textsuperscript{43} Briefly, electrocautery of the entire surface of the right kidney except for a 2 mm of intact tissue around the hilum was followed by left nephrectomy 2 weeks afterward. The casein-based high-phosphate diet was initiated after the second surgery. In the sham-operated animals, the kidneys were temporarily exposed but were not manipulated.

**Histology**

Kidney and ileum (last 10 mm) were harvested and fixed for 24 hours in 10% formalin, placed in 70% ethanol, embedded in paraffin, and sectioned. Sections were dewaxed in xylene, rehydrated by ethanol gradient, and stained in hematoxylin and eosin or von Kossa. For bone analysis mice were given an intraperitoneal injection of calcein (15 mg/kg) 8 days before sacrifice and alizarin red (40 mg/kg) 3 days before sacrifice. Femurs were fixed in 40% alcohol and processed in methyl methacrylate. Each femur was sectioned at two levels per block separated by 100 μm in the ventral/dorsal plane. At each level, five serial 5-μm sections were obtained. Goldner’s Trichrome and von Kossa sections were analyzed for static measurements using the Osteo II Bioquant system (Bioquant, Nashville, TN). Unstained serial sections were used for dynamic measurements using the Osteo II Bioquant system. Nomenclature is in agreement with recommendations by Parfitt et al.\textsuperscript{44}
Immunofluorescence
Paraffin slides were dewaxed and rehydrated followed by antigen retrieval using sodium citrate solution (pH 9.9; Dako, Carpinteria, CA) and placed in pressure cooker for 15 minutes. Cooled slides were blocked in 5% goat serum/0.1% Triton 100/PBS for 1 hour. Ileum sections were incubated with rabbit anti-mouse Npt2b (1 µg/ml), raised against a carboxy-terminal peptide (CQVEVLSMKALSNTTVF). Blocking and primary antibody incubations were in 5% goat serum/PBS base. Goat anti-rabbit IgG conjugated to Alexa Fluor 488 (Invitrogen, Grand Island, NY) was used to detect rabbit anti-mouse primary and phalloidin conjugated to Alexa Fluor 594 (Invitrogen) was used to detect actin filaments. Covers slips were mounted with VectaShield hard set mounting media (VectorLabs, Burlingame, CA). Images were captured on a Zeiss AxioVert 200 microscope.

Immunoblot Analyses
Tissue isolated as described above was homogenized in tissue protein extraction reagent (T-PER) (Thermo Fisher Scientific, Rockford, IL) in the presence of complete protease inhibitors (Roche Diagnostics, Indianapolis, IN) and phenylmethylsulphonyl fluoride (Sigma, St. Louis, MO). Total lysate from ileum (40 µg) were subjected to electrophoresis on Nu-PAGE gel (Invitrogen) and detected using rabbit anti-mouse Npt2b (1 µg/ml). Blocking and primary antibody incubations were in 5% goat serum/PBS base. Goat anti-rabbit IgG conjugated to Alexa Fluor 488 (Invitrogen, Grand Island, NY) was used to detect rabbit anti-mouse primary and phalloidin conjugated to Alexa Fluor 594 (Invitrogen) was used to detect actin filaments. Blots were normalized to β-actin primary antibody directly conjugated to horseradish peroxidase (Cell Signal Technologies). Autoradiographs were scanned, and the ratio of Npt2b to β-actin was quantified by image analysis, using ImageJ software (National Institutes of Health, Bethesda, MD).

Serum and Urine Analyses
Whole blood was collected under isoflurane anesthesia via retro-orbital bleed, incubated for 20 minutes at room temperature, and then centrifuged at 4°C. Serum was aliquoted and frozen at −80°C for subsequent analysis. Animals were placed in metabolic cages in which urine and feces were collected over a 24-hour period. Urine was centrifuged to remove particulates and the resultant supernatant volume recorded. All serum and urine phosphate, calcium, BUN, and creatinine (enzymatic methods) were measured on an Integra 400 bioanalyzer (Roche Diagnostics, Indianapolis, IN). Intact PTH (Immutopics, San Clemente, CA) and intact FGF23 (Kainos, Tokyo, Japan) ELISAs were performed according to the manufacturers’ instructions.

Fecal Phosphate Analyses
Stool samples were collected over a 24-hour period and contaminating food was removed. Fecal samples were weighed and lyophilized overnight. The dry weight of stool sample was reconstituted in 0.6 M hydrochloric acid (Sigma) to a final concentration of 50 mg/ml for 3 days under gentle rotation. On the second day of extraction, samples were homogenized, mixed for 24 hours, and then centrifuged at 2000 RCF for 5 minutes to remove particulate matter. A portion of supernatant was diluted 1:100 with HPLC (Baker) grade water. Fecal phosphate was quantified according to the manufacturer’s protocol (Stanbio Laboratories).

Statistical and Correlation Analyses
All serum, urine, and fecal biochemical data were calculated using the Man–Whitney nonparametric test. The t test was used to analyze significance between two groups for all other endpoints. P values <0.05 was considered significant.

Correlation analysis between serum phosphate and BUN was performed using linear regression for each genotype (combining chow, adenine, and adenine and sevelamer treatment) and plotted on the same graph. Subgroup analysis for each of the treatment groups was performed by performing a linear regression for each of the uremic groups and the slope of best-fit plotted.

ACKNOWLEDGMENTS
We thank the following colleagues from Genzyme: William Weber for imaging analysis, Leah Curtin for colony management, and Michael Phipps and Matthew DeRiso for genotyping.

A portion of this work was presented at the 2011 Annual Meeting of the American Society of Nephrology, November 10–13, 2011, in Philadelphia, Pennsylvania.

DISCLOSURES
All authors are employees of Genzyme, a Sanofi company.

REFERENCES


32. Parfitt AM: Misconceptions (3): Calcium leaves bone only by resorption and enters only by formation. Bone 33: 259–263, 2003


This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2011121213/-/DCSupplemental.